Compound · clinical trials

Dexamethasone clinical trials

Also listed in trial records as Decadron, Dexahexal, CI632D, D1-5, Prednisoneacetatetablets, Baycadron, Fortecortin, Aacidexam, Adexone, Alba-Dex, Alin

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 341 trials in our China, France, USA, Spain, Canada, Australia, Israel, Germany, Italy, Poland, Japan, UK, South Korea, Netherlands, Brazil, Denmark, Sweden, Czechia, Belgium, Turkey, Norway, Mexico, Taiwan, Austria, Egypt, Switzerland, Portugal, Ireland, Singapore and India registers that name Dexamethasone as an intervention. Synced 9 Nov 2026

341Current trials

190Recruiting now

171Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Dexamethasone is named as an intervention in 341 current clinical trials in our China, France, USA, Spain, Canada, Australia, Israel, Germany, Italy, Poland, Japan, UK, South Korea, Netherlands, Brazil, Denmark, Sweden, Czechia, Belgium, Turkey, Norway, Mexico, Taiwan, Austria, Egypt, Switzerland, Portugal, Ireland, Singapore and India registers. 190 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is GlaxoSmithKline (14). The most-studied condition is Multiple Myeloma. The EU clinical trials register (CTIS) separately lists 16 authorised or ongoing trials.

Where Dexamethasone is approved

All regulators →

Of the three regulators tracked here, the first to approve Dexamethasone was the US, on 30 Oct 1958. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)

30 Oct 1958

Decadron

NDA011664 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

26 Jul 2010

Ozurdex

EMA product page

First centralised authorisation

CACanada (Health Canada)

10 Feb 2011

Ozurdex

Notice of Compliance 12057

First new-drug NOC

4 EU orphan designations, most recently for treatment in haematopoietic stem cell transplantation (18 Nov 2016, withdrawn)
1 EU safety letter (DHPC), latest: change in dosing recommendation for Neofordex, 17 Feb 2023

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

Dexamethasone patents and exclusivity

Expiry tracker →

Protections still running for marketed products containing Dexamethasone, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.

US FDA Orange Book Ozurdex, Dextenza, Maxidex

7 listed patents; the last listed expires 26 Apr 2041 (US 12144889).
Exclusivity NPP: New patient population, until 7 Apr 2028.

See the Orange Book listing for NDA 022315

Patents and exclusivities above are pooled across 4 applications for this substance.

Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.

What health systems spend on Dexamethasone

All medicines →

ENNHS England

£15.2m

1,704,394 items dispensed, Sep 2025 to Aug 2026

+33% on the previous 12 months

Net ingredient cost, community prescriptions

USUS Medicaid

$21.9m

2,795,394 prescriptions in 2025 · Dexamethasone Sodium Phosphate, Ozurdex, Dexamethasone

-67% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Dexamethasone works

All drug targets →

Glucocorticoid receptor agonist Agonist
Target: NR3C1 nuclear receptor subfamily 3 group C member 1
✓ In ChEMBL and the Guide to Pharmacology

Other medicines acting on NR3C1

Prednisone Methylprednisolone Prednisolone Hydrocortisone Budesonide Triamcinolone Acetonide Mometasone furoate Triamcinolone Betamethasone Relacorilant Mifepristone Clobetasol Propionate +3 more

Diseases it has been tested for in clinical trials, by furthest phase

AL amyloidosisPhase 3
Acanthamoeba keratitisPhase 3
B-cell acute lymphoblastic leukemiaPhase 3
Behcet diseasePhase 3
Burkitt lymphomaPhase 3
COVID-19Phase 3
COVID-19–associated multisystem inflammatory syndrome in childrenPhase 3
Digital flexor tenosynovitisPhase 3
DysmenorrheaPhase 3
DysphagiaPhase 3

293 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL384467, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2768, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Dexamethasone

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 4 technology appraisals of Dexamethasone. 3 are current, and 3 of these recommend it for at least some patients. 1 older appraisal was replaced or withdrawn.

Appraisal	NICE recommendation	Published	Status
Dexamethasone intravitreal implant for treating diabetic macular oedema NICE TA824	Optimised	14 Sep 2022	Current
Adalimumab and dexamethasone for treating non-infectious uveitis NICE TA460	Optimised	26 Jul 2017	Current
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion NICE TA229	Recommended Optimised	27 Jul 2011	Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Dexamethasone

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 20 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
EU
European Union: Neofordex, Ozurdex
EMA product information: package leaflet and summary of product characteristics in every EU language.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Dexamethasone

ATC codes: S03BA01, S02BA06, S01CB01, S01BA01, R01AD03, H02AB02, D10AA03, D07XB05, D07AB19, C05AA09, A01AC02
ChEMBL: CHEMBL384467
DrugBank: DB01234
PubChem CID: 5743
CAS number: 50-02-2
FDA UNII: 7S5I7G3JQL
Wikidata: Q422252
Wikipedia: Dexamethasone

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting19056%
Not yet open3310%
Active, closed11534%
By invitation31%

Trials by phase

Phase 311634%
Phase 28625%
Phase 1/24012%
Not applicable3911%
Phase 4216%
Phase 2/3165%
Phase 1154%
Observational62%
Early Phase 121%

Clinical trials of Dexamethasone

341 trials

Study	Phase	Status	Lead sponsor	Registers
Intravenous Dexamethasone Administration in Patients Undergoing Total Shoulder Arthroplasty NCT04507412 · ClinicalTrials.gov ↗ · Arthroplasty, Replacement, Shoulder	Phase 4	Recruiting	Christian Candrian	Switzerland
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block NCT05793060 · ClinicalTrials.gov ↗ · Analgesia	Phase 4	Recruiting	Damanhour Teaching Hospital	Egypt
Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment NCT06118710 · ClinicalTrials.gov ↗ · Cancer	Phase 4	Recruiting	Erasmus Medical Center	Netherlands
Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection NCT06268704 · ClinicalTrials.gov ↗ · Sacroiliac Joint Dysfunction, Sacro-Iliac Spondylosis	Phase 4	Recruiting	University of New Mexico	Mexico
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection NCT06409702 · ClinicalTrials.gov ↗ · Newly Diagnosed, High Risk, MRD	Phase 4	Recruiting	The First Affiliated Hospital of Soochow University	China
Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss NCT06968507 · ClinicalTrials.gov ↗ · Sudden Sensorineural Hearing Loss	Phase 4	Recruiting	Dr. Lutfi Kirdar Kartal Training and Research Hospital	Turkey
Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) NCT07025005 · ClinicalTrials.gov ↗ · Peripheral Neuropathy, Multiple Myeloma, Neoplasms	Phase 4	Recruiting	Tanta University	Egypt
The Effect of Corticosteroids on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study NCT07378215 · ClinicalTrials.gov ↗ · Postoperative Quality of Recovery, Health-Related Quality-of-Life, Quality of Life	Phase 4	Recruiting	Ziekenhuis Oost-Limburg	Belgium
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC NCT07482891 · ClinicalTrials.gov ↗ · Chemotherapy-induced Nausea and Vomiting	Phase 4	Recruiting	Shanghai 6th People's Hospital	China
Dex & Mastectomy Pain NCT07556952 · ClinicalTrials.gov ↗ · Post-Mastectomy Chronic Pain Syndrome	Phase 4	Recruiting	McGill University Health Centre/Research Institute of the McGill University Health Centre	Canada
Intravenous Dexamethasone With Single-Shot Versus Continuous Brachial Plexus Block for Rebound Pain After Shoulder Surgery NCT07699744 · ClinicalTrials.gov ↗ · Pain, Postoperative, Rebound Pain, Shoulder Injuries	Phase 4	Recruiting	Seoul National University Hospital	South Korea
Success Rates and Safety of Steroid Injections in Managing Spinal and Sacro-Iliac Pain (CORTisone Injection Spine Study) NCT07762170 · ClinicalTrials.gov ↗ · Back Pain Lower Back, Neck Pain, Radiculopathy Multiple Sites	Phase 4	Recruiting	Igor Wilderman. MD	Canada
Low-Volume Pericapsular Nerve Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After Total Hip Arthroplasty NCT07855341 · ClinicalTrials.gov ↗ · Pain, Postoperative, Muscle Weakness, Arthroplasty, Replacement, Hip	Phase 4	Recruiting	Ain Shams University	Egypt
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia NCT03150693 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Canada, Mexico, Israel
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 NCT03643276 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric	Phase 3	Recruiting	Martin Schrappe	Germany, Italy, Switzerland, Austria, Czechia, Australia, Israel
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma NCT03937635 · ClinicalTrials.gov ↗ · Smoldering Plasma Cell Myeloma	Phase 3	Recruiting	ECOG-ACRIN Cancer Research Group	Egypt
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy NCT03959085 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma NCT04043494 · Lymphoblastic Lymphoma, Childhood	Phase 3	Recruiting	University Hospital Muenster	Ireland, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Israel
Randomised Evaluation of COVID-19 Therapy NCT04381936 · ClinicalTrials.gov ↗ · Pneumonia	Phase 3	Recruiting	University of Oxford	India, France, Spain, Italy, Netherlands, Belgium, Sweden, Portugal
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial NCT04566328 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma	Phase 3	Recruiting	ECOG-ACRIN Cancer Research Group	Mexico
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) NCT04638790 · Hodgkin Lymphoma, Adult	Phase 3	Recruiting	State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia	India
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments NCT05020236 · Multiple Myeloma	Phase 3	Recruiting	Pfizer	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Austria, Czechia, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Dexamethasone in Traumatic Brain Injury NCT05323149 · ClinicalTrials.gov ↗ · Inflammatory Response	Phase 3	Recruiting	Assiut University	Egypt
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085 · Relapsed or Refractory Multiple Myeloma	Phase 3	Recruiting	Celgene	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma NCT05552222 · Multiple Myeloma	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide NCT05558319 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma	Phase 3	Recruiting	PETHEMA Foundation	Spain
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment NCT05561387 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma	Phase 3	Recruiting	SWOG Cancer Research Network	Mexico
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant NCT05623020 · Multiple Myeloma	Phase 3	Recruiting	Pfizer	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses) NCT05668455 · ClinicalTrials.gov ↗ · Ocular Inflammation, Ocular Prostheses	Phase 3	Recruiting	Agnes	France
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma NCT05730036 · Relapsed Refractory Multiple Myeloma (RRMM)	Phase 3	Recruiting	Regeneron Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis NCT06022939 · ClinicalTrials.gov ↗ · AL Amyloidosis	Phase 3	Recruiting	SWOG Cancer Research Network	Egypt
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624 · Prostate Cancer Metastatic	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650 · Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Sweden, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) NCT06152575 · Multiple Myeloma	Phase 3	Recruiting	Pfizer	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Czechia, Norway, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel, Egypt
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma NCT06182774 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	Canadian Cancer Trials Group	Canada
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) NCT06187441 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	Stichting Hemato-Oncologie voor Volwassenen Nederland	Netherlands
Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children NCT06208917 · ClinicalTrials.gov ↗ · Pediatric Solid Tumor, Unspecified, Protocol Specific	Phase 3	Recruiting	Yizhuo Zhang	China
TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children NCT06259006 · ClinicalTrials.gov ↗ · Rheumatic Fever, Sydenham Chorea	Phase 3	Recruiting	Starship Child Health, Te Toka Tumai Auckland	Australia
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype NCT06269900 · ClinicalTrials.gov ↗ · Hospital Acquired Pneumonia	Phase 3	Recruiting	Nantes University Hospital	France, Spain
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL NCT06361329 · ClinicalTrials.gov ↗ · ETP-ALL	Phase 3	Recruiting	First Affiliated Hospital of Zhejiang University	China
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients NCT06508983 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma	Phase 3	Recruiting	Hangzhou Sumgen Biotech Co., Ltd	China
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone NCT06561854 · ClinicalTrials.gov ↗ · Multiple Myeloma, Relapse Multiple Myeloma	Phase 3	Recruiting	Assistance Publique - Hôpitaux de Paris	France
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)	Phase 3	Recruiting	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma	Phase 3	Recruiting	GlaxoSmithKline	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Corticosteroids Before Extubation in Pediatric Intensive Care Unit NCT06722118 · ClinicalTrials.gov ↗ · Intensive Care Pediatric	Phase 3	Recruiting	Assistance Publique - Hôpitaux de Paris	France
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) NCT06824467 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases NCT06888817 · ClinicalTrials.gov ↗ · Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases	Phase 3	Recruiting	The Netherlands Cancer Institute	Netherlands
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients NCT06918002 · ClinicalTrials.gov ↗ · Multiple Myeloma, Newly Diagnosed	Phase 3	Recruiting	Intergroupe Francophone du Myelome	France, Belgium
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant NCT06932562 · Multiple Myeloma	Phase 3	Recruiting	European Myeloma Network B.V	Ireland, Germany, Spain, Italy, Netherlands, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Australia
Effect of Early Dexamethasone on Major Complications and All-cause Mortality in Severe Burns NCT06968559 · ClinicalTrials.gov ↗ · Severe Burns	Phase 3	Recruiting	Nantes University Hospital	France
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma NCT07138209 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol NCT07152041 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic	Phase 3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT07222761 · Relapsed and/or Refractory Multiple Myeloma (RRMM)	Phase 3	Recruiting	Regeneron Pharmaceuticals	UK, USA, Turkey, Brazil, South Korea, Taiwan, Australia
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT07297329 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM)	Phase 3	Recruiting	Sinocelltech Ltd	China
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma NCT07327216 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	Affiliated Hospital of Guangdong Medical University	China
Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions NCT07362914 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Fudan University	China
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) NCT07388602 · ClinicalTrials.gov ↗ · Amyloidosis	Phase 3	Recruiting	Sinocelltech Ltd	China
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) NCT07391657 · Relapsed Refractory Multiple Myeloma	Phase 3	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Poland, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen NCT07413809 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	The Affiliated People's Hospital of Ningbo University	China
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma NCT07452198 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	Genrix (Shanghai) Biopharmaceutical Co., Ltd	China
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma NCT07555938 · Multiple Myeloma	Phase 3	Recruiting	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Denmark, Poland, Czechia, Canada, Brazil, Japan, South Korea, Australia, Israel
High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia NCT07559331 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia (ITP)	Phase 3	Recruiting	Shandong University	China
Dexamethasone Treatment for Sepsis-associated Acute Respiratory Distress Syndrome: a Multicenter, Randomised, Double-blinded, Controlled Trial NCT07576660 · ClinicalTrials.gov ↗ · Acute Respiratory Distress Syndrome (ARDS)	Phase 3	Recruiting	Southeast University, China	China
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma NCT07579234 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma (RRMM)	Phase 3	Recruiting	Shandong New Time Pharmaceutical Co., LTD	China
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM NCT07624513 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	Dana-Farber Cancer Institute	Israel
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned NCT07665450 · Multiple Myeloma	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, Germany, France, Spain, Italy, Netherlands, Poland, Czechia, Portugal, Turkey, South Korea, Australia, Israel
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide NCT07716176 · ClinicalTrials.gov ↗ · Nausea and Vomiting Caused by Chemotherapy	Phase 3	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan NCT07716189 · ClinicalTrials.gov ↗ · Nausea and Vomiting Caused by Trastuzumab Deruxtecan	Phase 3	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound NCT07716228 · ClinicalTrials.gov ↗ · Nausea and Vomiting Caused by Chemotherapy	Phase 3	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT NCT07764978 · Newly Diagnosed Multiple Myeloma	Phase 3	Recruiting	AstraZeneca	UK, USA, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma NCT07772024 · Multiple Myeloma Refractory, Multiple Myeloma in Relapse	Phase 3	Recruiting	CellCentric Ltd	USA
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR NCT02416388 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 2/3	Recruiting	University Hospital, Angers	France
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients NCT05665140 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma	Phase 2/3	Recruiting	University Hopsital Schleswig Holstein Campus Lübeck	Germany
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma NCT05991388 · ClinicalTrials.gov ↗ · B-cell Non Hodgkin Lymphoma	Phase 2/3	Recruiting	University of Birmingham	Netherlands, Belgium, Sweden, Austria, Australia
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) NCT06616584 · ClinicalTrials.gov ↗ · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8	Phase 2/3	Recruiting	SWOG Cancer Research Network	Mexico
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol NCT06764238 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)	Phase 2/3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Newly-diagnosed Pediatric T-cell ALL Protocol NCT06855810 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma	Phase 2/3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol NCT06882057 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)	Phase 2/3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT07095452 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2/3	Recruiting	AbbVie	USA, France, Spain, Japan
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL NCT07185373 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma	Phase 2/3	Recruiting	Huashan Hospital	China
High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy NCT07213375 · ClinicalTrials.gov ↗ · Analgetic, Lung Cancer (NSCLC), Video Assisted Thoracic Surgery (VATS)	Phase 2/3	Recruiting	Copenhagen University Hospital, Rigshospitalet	Denmark
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	France, Spain, Italy, Netherlands, Sweden, Denmark, Canada, Japan, Israel
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. NCT04414475 · ClinicalTrials.gov ↗ · Multiple Myeloma, Refractory	Phase 2	Recruiting	Karyopharm Therapeutics Inc	Israel
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage NCT04440267 · ClinicalTrials.gov ↗ · Acute Leukemia of Ambiguous Lineage	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT04546399 · ClinicalTrials.gov ↗ · Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Australia, Israel
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery NCT04891289 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Memorial Sloan Kettering Cancer Center	Netherlands
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. NCT04915248 · ClinicalTrials.gov ↗ · Plasmablastic Lymphoma	Phase 2	Recruiting	Fondazione Italiana Linfomi - ETS	Italy
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma NCT05180097 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada, Australia
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients NCT05272826 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Recruiting	Canadian Myeloma Research Group	Canada
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia NCT05660473 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 NCT05695508 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Recruiting	University of Heidelberg Medical Center	Germany
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients NCT05727163 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Sun Yat-sen University	China
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma NCT05789303 · ClinicalTrials.gov ↗ · Multiple Myeloma, Relapse Multiple Myeloma	Phase 2	Recruiting	University of Chicago	Israel
Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries NCT05849857 · ClinicalTrials.gov ↗ · Lymphoma, Follicular	Phase 2	Recruiting	Oslo University Hospital	Norway
Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease NCT05986318 · ClinicalTrials.gov ↗ · Lung Cancer, Interstitial Lung Disease	Phase 2	Recruiting	David Palma	Canada
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia NCT06034561 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission	Phase 2	Recruiting	Instituto do Cancer do Estado de São Paulo	Brazil
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966 · ClinicalTrials.gov ↗ · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Ma-Spore ALL 2020 Study NCT06336395 · ClinicalTrials.gov ↗ · B Lymphoblastic Leukemia	Phase 2	Recruiting	National University Hospital, Singapore	Singapore
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis NCT06342466 · ClinicalTrials.gov ↗ · Systemic Amyloidosis	Phase 2	Recruiting	Jin Lu, MD	China
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL NCT06387121 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL NCT06489808 · ClinicalTrials.gov ↗ · Relapsed/Refractory Large B-Cell Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients NCT06505369 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Recruiting	North Estonia Medical Centre	Denmark, Norway
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL NCT06554626 · ClinicalTrials.gov ↗ · Precursor B-Cell Lymphoblastic Leukemia	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment NCT06904599 · ClinicalTrials.gov ↗ · Acute Graft Versus Host Disease	Phase 2	Recruiting	Hospital Universitario Dr. Jose E. Gonzalez	Mexico
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial NCT06992128 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia (ITP)	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma NCT07018050 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma	Phase 2	Recruiting	Qilu Pharmaceutical Co., Ltd	China
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2) NCT07065968 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia (ITP)	Phase 2	Recruiting	Peking University People's Hospital	China
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma NCT07096778 · Multiple Myeloma Refractory, Multiple Myeloma in Relapse	Phase 2	Recruiting	CellCentric Ltd	UK, USA
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients NCT07159620 · ClinicalTrials.gov ↗ · Adult T-cell Leukemia/Lymphoma	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease NCT07187167 · ClinicalTrials.gov ↗ · Rosai-Dorfman Disease	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis NCT07224672 · Amyloidosis	Phase 2	Recruiting	GlaxoSmithKline	UK, USA, Australia
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) NCT07227311 · Multiple Myeloma	Phase 2	Recruiting	GlaxoSmithKline	USA, Germany, France, Spain, Netherlands, Japan, South Korea
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT07284758 · Multiple Myeloma, Relapsed/Refractory Multiple Myeloma	Phase 2	Recruiting	C4 Therapeutics, Inc	UK, USA, France, Spain, Italy, Poland, Israel
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study NCT07334379 · ClinicalTrials.gov ↗ · Acute Hypoxemic Respiratory Failure	Phase 2	Recruiting	Lorenzo delSorbo	Canada
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis NCT07335887 · ClinicalTrials.gov ↗ · AL Amyloidosis (AL), t(11;14) Positive	Phase 2	Recruiting	Peking University People's Hospital	China
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) NCT07709000 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies	Phase 2	Recruiting	Merck Sharp & Dohme LLC	Israel
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) NCT07785609 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Malignant Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Switzerland
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma NCT07825064 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Recruiting	Hoffmann-La Roche	Germany
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma NCT07891923 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma (NDMM)	Phase 2	Recruiting	Tata Memorial Centre	India
Selinexor and Backbone Treatments of Multiple Myeloma Patients NCT02343042 · Multiple Myeloma	Phase 1/2	Recruiting	Karyopharm Therapeutics Inc	USA, Canada
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors NCT02813135 · ClinicalTrials.gov ↗ · Pediatric Cancer	Phase 1/2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France, Spain, Italy, Netherlands, Denmark
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies NCT04068597 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma	Phase 1/2	Recruiting	CellCentric Ltd	UK, USA, France, Spain, Sweden
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types NCT04300556 · Solid Tumor	Phase 1/2	Recruiting	Eisai Inc	UK, USA, France, Spain, Japan
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol NCT04643002 · Plasma Cell Myeloma Refractory	Phase 1/2	Recruiting	Sanofi	USA, Germany, France, Italy, Norway, South Korea, Australia, Israel
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer NCT04947189 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 1/2	Recruiting	St Vincent's Hospital, Sydney	Australia
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma NCT04973605 · Relapsed/Refractory Multiple Myeloma	Phase 1/2	Recruiting	BeOne Medicines	UK, USA, China, Germany, France, Spain, Italy, Canada, Brazil, South Korea, Singapore, Australia
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) NCT05319730 · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, Italy, Switzerland, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma NCT05372354 · Multiple Myeloma	Phase 1/2	Recruiting	Bristol-Myers Squibb	UK, USA, Spain, Norway, Canada
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma NCT05583617 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Recruiting	Hoffmann-La Roche	Germany, France, Spain, Poland, South Korea, Australia
Dexamethasone in the Prevention of Post-spinal Paralytic Ileus After Cesarean Section NCT05654649 · ClinicalTrials.gov ↗ · Postoperative Ileus	Phase 1/2	Recruiting	Assiut University	Egypt
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies NCT05658640 · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	Phase 1/2	Recruiting	Princess Maxima Center for Pediatric Oncology	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Norway, Israel
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments NCT05714839 · Multiple Myeloma	Phase 1/2	Recruiting	GlaxoSmithKline	UK, USA, China, Poland, Turkey, Brazil, Japan, South Korea, Taiwan, Australia, Israel
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05745714 · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	Phase 1/2	Recruiting	Princess Maxima Center for Pediatric Oncology	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Austria, Norway, Israel
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05751044 · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	Phase 1/2	Recruiting	Princess Maxima Center for Pediatric Oncology	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Austria, Norway, Israel
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II NCT05848687 · ClinicalTrials.gov ↗ · Lymphoblastic Leukemia	Phase 1/2	Recruiting	Tanja Andrea Gruber	Canada
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) NCT06087653 · Multiple Myeloma	Phase 1/2	Recruiting	Starton Therapeutics, Inc	USA
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma NCT06106945 · Multiple Myeloma	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Canada, Brazil, Japan, Australia
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma NCT06376721 · ClinicalTrials.gov ↗ · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma	Phase 1/2	Recruiting	Beijing Tongren Hospital	China
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma NCT06552559 · ClinicalTrials.gov ↗ · B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, CNS Metastases	Phase 1/2	Recruiting	Samsung Medical Center	South Korea
"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL NCT06559553 · ClinicalTrials.gov ↗ · NKTCL, Selinexor	Phase 1/2	Recruiting	Mingzhi Zhang	China
Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate NCT06616142 · ClinicalTrials.gov ↗ · Primary Aldosteronism	Phase 1/2	Recruiting	University Medical Center Groningen	Netherlands
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma NCT06645678 · ClinicalTrials.gov ↗ · Relapsed Refractory Multiple Myeloma (RRMM)	Phase 1/2	Recruiting	YOUNGIL KOH	South Korea, Singapore
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations NCT06892522 · Multiple Myeloma	Phase 1/2	Recruiting	AbbVie	UK, USA, Norway, Japan, Australia, Israel
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) NCT06953960 · Multiple Myeloma	Phase 1/2	Recruiting	AbbVie	UK, USA, Germany, France, Italy, Belgium, Sweden, Poland, Portugal, Japan, Australia, Israel
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma NCT06988488 · Multiple Myeloma	Phase 1/2	Recruiting	Celgene	UK, USA, China, Germany, Spain, Norway, Canada
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) NCT07387926 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Phase 1/2	Recruiting	Novartis Pharmaceuticals	South Korea, Taiwan, Australia, Israel
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer NCT04729114 · Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA, Mexico
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma NCT04910568 · Multiple Myeloma	Phase 1	Recruiting	Genentech, Inc	UK, USA, France, Spain, Italy, Denmark, Poland, Czechia, Canada, Japan, South Korea, Australia, Israel
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770 · ClinicalTrials.gov ↗ · Hematologic Malignancy, AML, ALL	Phase 1	Recruiting	Therapeutic Advances in Childhood Leukemia Consortium	Australia
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma NCT05651932 · Multiple Myeloma, Myeloma, Myeloma Multiple	Phase 1	Recruiting	K36 Therapeutics, Inc	USA, France, Spain, Canada
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma NCT06121843 · Multiple Myeloma	Phase 1	Recruiting	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	USA, Canada, Israel
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma NCT06433947 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma	Phase 1	Recruiting	Opna Bio LLC	USA
ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma NCT06518551 · ClinicalTrials.gov ↗ · Myeloma, Multiple Myeloma, Refractory Multiple Myeloma	Phase 1	Recruiting	Omar Nadeem, MD	Israel
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma NCT07032714 · ClinicalTrials.gov ↗ · Relapsed Refractory Multiple Myeloma (RRMM)	Phase 1	Recruiting	Massachusetts General Hospital	Israel
Prospective Cohort for Adult Hemophagocytosis NCT03117010 · ClinicalTrials.gov ↗ · Hemophagocytic Lymphohistiocytoses	Observational	Recruiting	Samsung Medical Center	South Korea
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block NCT04559425 · ClinicalTrials.gov ↗ · Heart Block Complete, Heart Block Second Degree	Observational	Recruiting	The Hospital for Sick Children	Germany, France, Netherlands, Sweden, Poland, Canada, Japan, Taiwan
Rapid dFLC Response Predict CHR in AL Amyloidosis NCT06627309 · ClinicalTrials.gov ↗ · Systemic AL Amyloidosis	Observational	Recruiting	Peking University People's Hospital	China
Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections NCT06894017 · ClinicalTrials.gov ↗ · Informed Consent, Preference, Patient	Observational	Recruiting	Copenhagen University Hospital, Rigshospitalet	Denmark
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD NCT07385131 · ClinicalTrials.gov ↗ · Inflammatory Bowel Disease (IBD), CD - Crohn's Disease, UC - Ulcerative Colitis	Observational	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients NCT07663253 · ClinicalTrials.gov ↗ · Multiple Myeloma	Observational	Recruiting	Shanghai Zhongshan Hospital	China
Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery NCT04209218 · ClinicalTrials.gov ↗ · Lung Cancer, Surgery, Blood Pressure Management	Not applicable	Recruiting	Peking University First Hospital	China
Restrictive Use of Dexamethasone in Glioblastoma NCT04266977 · ClinicalTrials.gov ↗ · Glioblastoma, Dexamethasone, Steroids	Not applicable	Recruiting	Insel Gruppe AG, University Hospital Bern	Switzerland
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH NCT05936086 · ClinicalTrials.gov ↗ · Hemophagocytic Syndrome	Not applicable	Recruiting	shifeng Lou	China
Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade NCT06080880 · ClinicalTrials.gov ↗ · Nausea With Vomiting Chemotherapy-Induced	Not applicable	Recruiting	Hubei Cancer Hospital	China
Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Pain Relief NCT06133712 · ClinicalTrials.gov ↗ · Carpal Tunnel, Dexmedetomidine, Ozone	Not applicable	Recruiting	Tanta University	Egypt
Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS NCT06188195 · ClinicalTrials.gov ↗ · Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome, Acute	Not applicable	Recruiting	The Second Affiliated Hospital of Chongqing Medical University	China
Optimize First-line Treatment for AL Amyloidosis With t (11; 14) NCT06192979 · ClinicalTrials.gov ↗ · Amyloidosis; Systemic, AL Amyloidosis	Not applicable	Recruiting	Jin Lu, MD	China
Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal Injury NCT06410443 · ClinicalTrials.gov ↗ · Radiation-Induced Intestinal Injury	Not applicable	Recruiting	General Hospital of Shenyang Military Region	China
The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP NCT06479317 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia With Positive ANA Antibodies	Not applicable	Recruiting	Yunfeng Cheng	China
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease NCT06793475 · ClinicalTrials.gov ↗ · Extramedullary Multiple Myeloma	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT NCT06900777 · ClinicalTrials.gov ↗ · Vitiligo, Child, Progressive Disease	Not applicable	Recruiting	Xijing Hospital	China
Dexamethasone Palmitate for PONV After Craniotomy NCT06988124 · ClinicalTrials.gov ↗ · Postoperative Nausea and Vomiting	Not applicable	Recruiting	Beijing Tiantan Hospital	China
Dexamethasone Palmitate for PONV After Open Surgery NCT06997419 · ClinicalTrials.gov ↗ · Postoperative Nausea and Vomiting, Dexamethasone Palmitate, Open Surgery	Not applicable	Recruiting	Beijing Tiantan Hospital	China
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Caudal Epidural Block NCT07056244 · ClinicalTrials.gov ↗ · İnguinal Hernia	Not applicable	Recruiting	Sohag University	Egypt
Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia NCT07139522 · ClinicalTrials.gov ↗ · Dexamethasone, Magnesium Sulphate, Adjuvant	Not applicable	Recruiting	Cairo University	Egypt
Dexamethasone vs Dexmedetomidine vs Combination as Adjuvants to Popliteal Sciatic Nerve Block in Children NCT07289620 · ClinicalTrials.gov ↗ · Ankle Disease, Foot Diseases	Not applicable	Recruiting	Poznan University of Medical Sciences	Poland
PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults NCT07327931 · ClinicalTrials.gov ↗ · Hip Osteoarthritis, Hip Pain Chronic	Not applicable	Recruiting	Poznan University of Medical Sciences	Poland
Dexamethasone, Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy NCT07329933 · ClinicalTrials.gov ↗ · GIT Function, Cholecystectomy, Laparoscopic, Dexamethasone	Not applicable	Recruiting	Benha University	Egypt
Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults NCT07330999 · ClinicalTrials.gov ↗ · Hip Osteoarthritis	Not applicable	Recruiting	Poznan University of Medical Sciences	Poland
Dexamethasone Palmitate for Postoperative Pain NCT07341854 · ClinicalTrials.gov ↗ · Pain, Postoperative, Dexamethasone Palmitate	Not applicable	Recruiting	Beijing Tiantan Hospital	China
Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery NCT07474909 · ClinicalTrials.gov ↗ · Hand Injuries and Disorders, Wrist Sprain	Not applicable	Recruiting	Poznan University of Medical Sciences	Poland
Sphenopalatine Ganglion Block as Adjuvant to General Anesthesia Regarding the Quality of Surgical Field in Trans-Sphenoidal Endoscopic Hypophysectomy NCT07569952 · ClinicalTrials.gov ↗ · Sphenopalatine Ganglion Block, General Anesthesia, Quality of Surgical Field	Not applicable	Recruiting	Cairo University	Egypt
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty NCT07581470 · ClinicalTrials.gov ↗ · Osteoarthritis, Hip, Hip Osteoarthritis	Not applicable	Recruiting	Poznan University of Medical Sciences	Poland
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty NCT07584200 · ClinicalTrials.gov ↗ · Arthropathy of Hip, Hip Osteoarthritis	Not applicable	Recruiting	Poznan University of Medical Sciences	Poland
Local Dexamethasone Administration in Symptomatic Irreversible Pulpitis NCT07672873 · ClinicalTrials.gov ↗ · Symptomatic Irreversible Pulpitis (SIP), Dental Pain	Not applicable	Recruiting	Marmara University	Turkey
ACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty NCT07677215 · Knee Osteoarthritis	Not applicable	Recruiting	Poznan University of Medical Sciences	Poland
Intraperitoneal Dexamethasone Spraying on Vagal Nerve-Rich Areas for Prevention of Hoarseness After Upper Abdominal Surgery NCT07722091 · ClinicalTrials.gov ↗ · Hoarseness, Post Operative Complicaiton	Not applicable	Recruiting	Fujian Medical University Union Hospital	China
Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors NCT07743827 · ClinicalTrials.gov ↗ · Olanzapine, Breast Cancer, Dexamethasone	Not applicable	Recruiting	Alexandria University	Egypt
Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial Fibrillation NCT07877519 · ClinicalTrials.gov ↗ · Paroxysmal Atrial Fibrillation	Not applicable	Recruiting	China National Center for Cardiovascular Diseases	China
Modified Thoracolumbar Interfascial Plane Block vs Retrolaminar Block for Pain in Lumbar Spine Surgeries NCT07883616 · ClinicalTrials.gov ↗ · Postoperative Pain After Spinal Surgery	Not applicable	Recruiting	Zagazig University	Egypt
Intratympanic Injection of Dexamethasone With Hyaluronic Acid in Treatment of Sudden Sensorineural Hearing Loss NCT06878599 · ClinicalTrials.gov ↗ · Sudden Sensorineural Hearing Loss (SSNHL)	Phase 4	Not yet open	Assiut University	Egypt
Effects of Intraarticular Tramadol and Tramadol-Dexamethasone on Postoperative Pain After Knee Arthroscopy NCT07064993 · ClinicalTrials.gov ↗ · Knee Arthroscopy, Postoperative Pain	Phase 4	Not yet open	Arzu Esen Tekeli	Turkey
Perineural Dexamethasone, Dexmedetomidine, or Their Combination to Reduces Rebound Pain After Supraclavicular Brachial Plexus Block NCT07299877 · ClinicalTrials.gov ↗ · Brachial Plexus Blocks	Phase 4	Not yet open	Al-Azhar University	Egypt
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen NCT07709884 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma, T(11;14), Sotoclax	Phase 4	Not yet open	The First Affiliated Hospital of Soochow University	China
Sleep Quality - Comparing the Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intraoperatively to Prevent Post Operative Nausea and Vomiting (SCORPION) NCT07777276 · ClinicalTrials.gov ↗ · Postoperative Sleep Quality, Postoperative Behaviour, Postoperative Recovery in Children	Phase 4	Not yet open	Telethon Kids Institute	Brazil, Australia
Intravenous Dexamethasone for ESP Block Analgesia in Children Undergoing Idiopathic Scoliosis Surgery NCT07890220 · ClinicalTrials.gov ↗ · Adolescent Idiopathic Scoliosis (AIS)	Phase 4	Not yet open	Poznan University of Medical Sciences	Poland
Cervical Facet Injection of Corticosteroids for the Management of Cervicobrachialgia NCT07084285 · ClinicalTrials.gov ↗ · Cervicobrachial Neuralgia	Phase 3	Not yet open	Assistance Publique - Hôpitaux de Paris	France
Therapeutics for Moderate and Severe Dengue NCT07543458 · ClinicalTrials.gov ↗ · Dengue, Severe Dengue, Mosquito-Borne Diseases	Phase 3	Not yet open	Oxford University Clinical Research Unit, Vietnam	Brazil
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma NCT07569757 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Not yet open	Chia Tai Tianqing Pharmaceutical Group Co., Ltd	China
Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy NCT07674576 · ClinicalTrials.gov ↗ · Knee Arthroscopy	Phase 3	Not yet open	CMC Ambroise Paré	France
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma NCT07728188 · Relapsed or Refractory Multiple Myeloma	Phase 3	Not yet open	AbbVie	UK, USA, Germany, France, Spain, Italy, Netherlands, Norway, Portugal, Canada, Taiwan, Australia, Israel
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma NCT07910903 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM)	Phase 3	Not yet open	Keymed Biosciences Co.Ltd	China
The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP NCT06913374 · ClinicalTrials.gov ↗ · Thrombocytopenia	Phase 2/3	Not yet open	Shandong University	China
Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases: NCT07542288 · ClinicalTrials.gov ↗ · Brain Metastases From Solid Tumors	Phase 2/3	Not yet open	The Second Affiliated Hospital of Hainan Medical University	China
Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms NCT06643689 · ClinicalTrials.gov ↗ · Esophageal Stricture, Esophageal Neoplasms	Phase 2	Not yet open	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia NCT07064889 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia	Phase 2	Not yet open	Peking University People's Hospital	China
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma NCT07247097 · ClinicalTrials.gov ↗ · Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible	Phase 2	Not yet open	Massachusetts General Hospital	Israel
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients NCT07301138 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 2	Not yet open	Ruijin Hospital	China
A Open-Label Phase in Participants With Multiple Myeloma NCT07764861 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Not yet open	Innovent Biologics (Suzhou) Co. Ltd	China
GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma NCT07768943 · ClinicalTrials.gov ↗ · Natural Killer/T-cell Lymphoma	Phase 2	Not yet open	Fudan University	China
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease NCT07811986 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM)	Phase 2	Not yet open	Institute of Hematology & Blood Diseases Hospital, China	China
Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma NCT07856069 · ClinicalTrials.gov ↗ · Medulloblastoma	Phase 2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma NCT07901868 · ClinicalTrials.gov ↗ · Multiple Myeloma Refractory, Multiple Myeloma in Relapse	Phase 2	Not yet open	PETHEMA Foundation	Spain
Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss NCT07404709 · ClinicalTrials.gov ↗ · Sudden Hearing Loss, Extracellular Vesicles	Phase 1/2	Not yet open	The Affiliated Hospital of Qingdao University	China
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma NCT07600151 · ClinicalTrials.gov ↗ · Myeloma Multiple, Myeloma	Phase 1/2	Not yet open	Universitätsklinikum Hamburg-Eppendorf	Germany
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma NCT07601100 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma	Phase 1/2	Not yet open	Dana-Farber Cancer Institute	Israel
Methylprednisolone vs Dexamethasone: Effects on Sugammadex Reversal, Pain, and Nausea in Adults NCT07187037 · ClinicalTrials.gov ↗ · Neuromuscular Block, Residual, Pain, Postoperative Nausea	Not applicable	Not yet open	Konya City Hospital	Turkey
Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis NCT07345819 · ClinicalTrials.gov ↗ · Orbital Cellulitis	Not applicable	Not yet open	The Hospital for Sick Children	Canada
Comparison of the Effects of Moderate- and High-Dose Glucocorticoids on Postoperative Recovery NCT07469332 · ClinicalTrials.gov ↗ · Postoperative Recovery, PONV	Not applicable	Not yet open	Ankara City Hospital Bilkent	Turkey
Application of Multimodal Intervention in the Prevention of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgery NCT07631910 · ClinicalTrials.gov ↗ · Nausea and Vomiting, Postoperative	Not applicable	Not yet open	Sir Run Run Shaw Hospital	China
Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine NCT07837674 · ClinicalTrials.gov ↗ · Spinal Anesthesia, Prolonged Sensory Block, Prolonged Motor Block	Not applicable	Not yet open	Centre hospitalier de l'Université de Montréal (CHUM)	Canada
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain NCT07923643 · ClinicalTrials.gov ↗ · Breast Cancer, Postoperative Pain, Chronic Postoperative Pain	Not applicable	Not yet open	Assiut University	Egypt
A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy NCT07662200 · ClinicalTrials.gov ↗ · Germ Cell Cancer	Early Phase 1	Not yet open	Ottawa Hospital Research Institute	Canada
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab NCT05669989 · Plasma Cell Myeloma	Phase 2	By invitation	Sanofi	USA, China, France, Spain, Italy, Sweden, Czechia, Brazil, Japan, South Korea, Taiwan, Australia
Dexamethasone vs Dexmedetomidine in Sphenopalatine Ganglion Block for Rhinoplasty Pain NCT07380139 · ClinicalTrials.gov ↗ · Post Operative Pain	Phase 1	By invitation	Ain Shams University	Egypt
Comparing Pain Relief Between Two Methods of Freezing Injections in Children Having Their Appendix Removed NCT06945263 · ClinicalTrials.gov ↗ · Laparoscopic Appendectomy	Not applicable	By invitation	University of British Columbia	Canada
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA NCT03829371 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 4	Active, closed	University of Turin, Italy	Italy
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery NCT04025840 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Surgery, Epidural Block	Phase 4	Active, closed	Peking University First Hospital	China
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma NCT00644228 · ClinicalTrials.gov ↗ · DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 NCT01208662 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	Paul Richardson, MD	Israel
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma NCT01863550 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma	Phase 3	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia NCT02003222 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia NCT02101853 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia, Israel
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma NCT02112916 · ClinicalTrials.gov ↗ · Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia NCT02339740 · ClinicalTrials.gov ↗ · Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA	Phase 3	Active, closed	Children's Oncology Group	Canada, Australia, Israel
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma NCT02659293 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	University of Chicago	Poland
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia NCT03007147 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia	Phase 3	Active, closed	Children's Oncology Group	Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Canada, Mexico, Australia, Israel
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents NCT03020030 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric	Phase 3	Active, closed	Dana-Farber Cancer Institute	Canada
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents NCT03206671 · Mature B-cell Non-Hodgkin Lymphoma	Phase 3	Active, closed	University Hospital Muenster	Germany, Sweden, Denmark, Switzerland, Austria, Czechia, Norway
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT03319667 · Plasma Cell Myeloma	Phase 3	Active, closed	Sanofi	USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Czechia, Portugal, Turkey, Mexico, Japan, Taiwan, Australia
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. NCT03539744 · Multiple Myeloma	Phase 3	Active, closed	AbbVie	UK, USA, China, Germany, France, Spain, Italy, Sweden, Denmark, Czechia, Turkey, Canada, Japan, South Korea, Singapore, Australia, Israel
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia NCT03589326 · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	Phase 3	Active, closed	Takeda	USA, China, France, Spain, Italy, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) NCT03617731 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	University of Heidelberg Medical Center	Germany
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma NCT03710603 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	Stichting European Myeloma Network	France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Czechia, Norway, Turkey, Australia
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years NCT03742297 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma	Phase 3	Active, closed	PETHEMA Foundation	Spain
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia NCT03914625 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM NCT03948035 · Newly Diagnosed Multiple Myeloma	Phase 3	Active, closed	Wuerzburg University Hospital	Germany, Austria
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant NCT04096066 · ClinicalTrials.gov ↗ · Multiple Myeloma, New Diagnosis Tumor	Phase 3	Active, closed	Fondazione EMN Italy Onlus	Italy
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT04162210 · Multiple Myeloma	Phase 3	Active, closed	GlaxoSmithKline	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Canada, Brazil, Japan, South Korea, Australia
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma NCT04181827 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Japan, South Korea, Australia, Israel
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT04246047 · Multiple Myeloma	Phase 3	Active, closed	GlaxoSmithKline	USA, China, Spain, Italy, Netherlands, Belgium, Poland, Japan, South Korea, Australia, Israel
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma NCT04270409 · Plasma Cell Myeloma	Phase 3	Active, closed	Sanofi	Ireland, UK, USA, China, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) NCT04474223 · ClinicalTrials.gov ↗ · AVB - Atrioventricular Block, Fetal AVB	Phase 3	Active, closed	NYU Langone Health	Canada, Mexico
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma NCT04484623 · Multiple Myeloma	Phase 3	Active, closed	GlaxoSmithKline	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Turkey, Brazil, Japan, South Korea, Australia, Israel
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults NCT04530565 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). NCT04751877 · ClinicalTrials.gov ↗ · Multiple Myeloma, Myeloma	Phase 3	Active, closed	Poitiers University Hospital	France
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy NCT04923893 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	Ireland, UK, USA, Germany, France, Spain, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Canada, Brazil, Japan, South Korea, Australia, Israel
MInimal Residual Disease Adapted Strategy NCT04934475 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	Intergroupe Francophone du Myelome	France, Belgium
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT04975997 · Multiple Myeloma	Phase 3	Active, closed	Celgene	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma NCT05028348 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	European Myeloma Network B.V	Germany, France, Spain
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma NCT05083169 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma NCT05257083 · Multiple Myeloma	Phase 3	Active, closed	Stichting European Myeloma Network	Germany, France, Spain, Netherlands, Belgium, Sweden, Switzerland, Czechia, Norway, Canada, Japan, Australia, Israel
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia NCT05325593 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia	Phase 3	Active, closed	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Spain, Italy
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM NCT05405166 · Plasma Cell Myeloma Recurrent	Phase 3	Active, closed	Sanofi	UK, USA, China, Germany, France, Spain, Italy, Sweden, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, Taiwan, Australia
A Study of Daratumumab NCT05438043 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Turkey, Brazil, South Korea
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment NCT05455320 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Turkey, Brazil, Japan, South Korea, Taiwan, Israel
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) NCT05552976 · Relapsed or Refractory Multiple Myeloma	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA, India, China, Germany, Spain, Italy, Netherlands, Denmark, Austria, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma NCT05572515 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, Australia, Israel
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) NCT05738486 · Alzheimer's Disease, Dementia, Brain Diseases	Phase 3	Active, closed	Eli Lilly and Company	UK, USA
The Danish Out-of-Hospital Cardiac Arrest Study NCT05895838 · ClinicalTrials.gov ↗ · Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome	Phase 3	Active, closed	Christian Hassager	Denmark
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma NCT06158841 · Multiple Myeloma	Phase 3	Active, closed	AbbVie	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Portugal, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide NCT06208150 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma NCT06216158 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	University of Heidelberg Medical Center	Germany, Austria
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma NCT06230224 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma (B-NHL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	Spain, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) NCT06305754 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA, India, China, France, Spain, Italy, Sweden, Poland, Turkey, Canada, Mexico, Japan, South Korea, Taiwan
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma NCT06413498 · Multiple Myeloma	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Canada, Mexico, Japan, Australia
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) NCT06464991 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	Nanjing IASO Biotechnology Co., Ltd	China, Japan
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT06868654 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	GlaxoSmithKline	China
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT06868667 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	GlaxoSmithKline	Japan
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma NCT06956170 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	GlaxoSmithKline	Japan
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma NCT03117751 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma	Phase 2/3	Active, closed	St. Jude Children's Research Hospital	Australia
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT04442022 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-cell Lymphoma	Phase 2/3	Active, closed	Karyopharm Therapeutics Inc	USA, China, Spain, Italy, Poland, Israel
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) NCT05096663 · ClinicalTrials.gov ↗ · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8	Phase 2/3	Active, closed	SWOG Cancer Research Network	Mexico, Egypt
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma NCT02415413 · ClinicalTrials.gov ↗ · Smoldering Multiple Myeloma	Phase 2	Active, closed	PETHEMA Foundation	Spain
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma NCT02436707 · ClinicalTrials.gov ↗ · Lymphoma	Phase 2	Active, closed	Canadian Cancer Trials Group	Canada
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) NCT02899052 · Multiple Myeloma	Phase 2	Active, closed	AbbVie	USA, Spain, Australia
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma NCT03030261 · ClinicalTrials.gov ↗ · Multiple Myeloma in Relapse	Phase 2	Active, closed	Washington University School of Medicine	Canada
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone NCT03104842 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Universitätsklinikum Hamburg-Eppendorf	Germany
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma NCT03314181 · Multiple Myeloma	Phase 2	Active, closed	AbbVie	USA, Germany, France, Denmark, Canada, Japan, Australia, Israel
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. NCT03314636 · ClinicalTrials.gov ↗ · Myeloma	Phase 2	Active, closed	Oslo University Hospital	Sweden, Denmark, Norway
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients NCT03376672 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Raija Silvennoinen	Sweden, Norway
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma NCT03589222 · ClinicalTrials.gov ↗ · Refractory Multiple Myeloma	Phase 2	Active, closed	PETHEMA Foundation	Spain
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients NCT03606577 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Nantes University Hospital	France
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM NCT03673826 · ClinicalTrials.gov ↗ · Smouldering Myeloma	Phase 2	Active, closed	Stichting Hemato-Oncologie voor Volwassenen Nederland	Italy, Netherlands, Czechia, Norway
A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients NCT04124497 · ClinicalTrials.gov ↗ · Multiple Myeloma, Deletion 17P Syndrome	Phase 2	Active, closed	Fondazione EMN Italy Onlus	Italy
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma NCT04133636 · Multiple Myeloma	Phase 2	Active, closed	Janssen Research & Development, LLC	USA, Germany, France, Spain, Netherlands, Belgium, Israel
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease NCT04166565 · ClinicalTrials.gov ↗ · Multiple Myeloma, Extramedullary Plasmacytoma	Phase 2	Active, closed	Stichting European Myeloma Network	Italy, Turkey
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM NCT04176718 · Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse	Phase 2	Active, closed	Andrew Yee, MD	Israel
KRDI in Transplant-Eligible MM NCT04430894 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients NCT04717700 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Ida Bruun Kristensen	Denmark, Norway
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma NCT04782687 · Multiple Myeloma, Myeloma Multiple, Kahler Disease	Phase 2	Active, closed	US Oncology Research	USA
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients NCT04802356 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	PETHEMA Foundation	Spain
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM NCT04891809 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma	Phase 2	Active, closed	Arbeitsgemeinschaft medikamentoese Tumortherapie	Austria
A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." NCT04998786 · ClinicalTrials.gov ↗ · Multiple Myeloma at First Relapse	Phase 2	Active, closed	Nantes University Hospital	France
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP NCT05023915 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia	Phase 2	Active, closed	Shandong University	China
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma NCT05123131 · Multiple Myeloma	Phase 2	Active, closed	Cancer Trials Ireland	Ireland, Denmark
Loncastuximab Tesirine in WM NCT05190705 · ClinicalTrials.gov ↗ · Waldenstrom Macroglobulinemia	Phase 2	Active, closed	Shayna Sarosiek, MD	Israel
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis NCT05250973 · Amyloidosis	Phase 2	Active, closed	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Canada
Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia NCT05303792 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma	Phase 2	Active, closed	Alliance for Clinical Trials in Oncology	Mexico
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. NCT05527340 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	PETHEMA Foundation	Spain
Premedication to Reduce Amivantamab Associated Infusion Related Reactions NCT05663866 · Carcinoma, Non-Small-Cell Lung	Phase 2	Active, closed	Janssen Research & Development, LLC	USA, France, Spain, South Korea, Taiwan
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma NCT05704049 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma	Phase 2	Active, closed	Sanofi	China, Czechia, Portugal, Brazil, Japan, Australia
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients NCT05751187 · ClinicalTrials.gov ↗ · Non-squamous NSCLC	Phase 2	Active, closed	Shanghai Chest Hospital	China
Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) NCT05996406 · ClinicalTrials.gov ↗ · Light Chain (AL) Amyloidosis, CCND1 Translocation, Venetoclax	Phase 2	Active, closed	Peking Union Medical College Hospital	China
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma NCT06353022 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Nantes University Hospital	France
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma NCT06356571 · Plasma Cell Myeloma Refractory	Phase 2	Active, closed	Sanofi	USA, Israel
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma NCT06577025 · Multiple Myeloma	Phase 2	Active, closed	Janssen Research & Development, LLC	USA, Germany, Spain, Brazil, Australia
Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) NCT06629818 · ClinicalTrials.gov ↗ · Light Chain (AL) Amyloidosis	Phase 2	Active, closed	Peking Union Medical College Hospital	China
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · Lung Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey
Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH NCT07204041 · ClinicalTrials.gov ↗ · Langerhans Cell Histiocytosis (LCH)	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL NCT07480863 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL)	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors NCT07841210 · ClinicalTrials.gov ↗ · Solid Tumor Cancer	Phase 2	Active, closed	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma NCT00378105 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Active, closed	Dana-Farber Cancer Institute	Israel
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I NCT02553460 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 1/2	Active, closed	St. Jude Children's Research Hospital	Canada
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma NCT02773030 · Multiple Myeloma	Phase 1/2	Active, closed	Celgene	UK, USA, Germany, France, Spain, Italy, Netherlands, Canada, Japan, Australia, Israel
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma NCT03817320 · ClinicalTrials.gov ↗ · ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood	Phase 1/2	Active, closed	Therapeutic Advances in Childhood Leukemia Consortium	Australia
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) NCT03989414 · Multiple Myeloma	Phase 1/2	Active, closed	Celgene	USA, Germany, France, Spain, Italy, Denmark, Czechia, Canada
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT04126200 · Multiple Myeloma	Phase 1/2	Active, closed	GlaxoSmithKline	USA, Germany, France, Spain, Netherlands, Sweden, Poland, Norway, Canada, Brazil, Mexico, South Korea
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide NCT05060627 · ClinicalTrials.gov ↗ · Relapsed Multiple Myeloma	Phase 1/2	Active, closed	PETHEMA Foundation	Spain
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386 · Prostatic Neoplasms, Castration-Resistant	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Denmark, Poland, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM NCT07150091 · Multiple Myeloma	Phase 1/2	Active, closed	GlaxoSmithKline	USA, Germany, France, Canada, Brazil, Mexico, South Korea
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM NCT07150104 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Active, closed	GlaxoSmithKline	France, Sweden, Poland, Norway, Canada, Brazil, Mexico, South Korea
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma NCT04091126 · Multiple Myeloma	Phase 1	Active, closed	GlaxoSmithKline	UK, USA, Germany, France, Spain, Italy, Poland, Canada, South Korea, Australia
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. NCT04667663 · Multiple Myeloma	Phase 1	Active, closed	Cancer Trials Ireland	Ireland
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma NCT04756726 · ClinicalTrials.gov ↗ · Multiple Myeloma, Lymphoma, Non-Hodgkin's	Phase 1	Active, closed	C4 Therapeutics, Inc	USA
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma NCT05259839 · Relapsed/Refractory Multiple Myeloma	Phase 1	Active, closed	AbbVie	USA, Germany, Spain, Italy, Poland, Japan, Australia
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets NCT05308654 · Relapsed/Refractory Multiple Myeloma	Phase 1	Active, closed	AbbVie	UK, USA, Australia, Israel
A Rollover Study of CC-122 NCT05688475 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma	Phase 1	Active, closed	Bristol-Myers Squibb	USA, France, Netherlands, Japan
Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array NCT06598059 · Hearing Loss	Not applicable	Active, closed	Cochlear	USA
Effect of Preoperative Long-Acting Corticosteroids on Pain, Swelling, and Trismus After Impacted Lower Third Molar Surgery NCT07450638 · ClinicalTrials.gov ↗ · Impacted Mandibular Third Molar, Postoperative Pain, Trismus	Not applicable	Active, closed	Al Salam University	Egypt
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma NCT04161248 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell	Early Phase 1	Active, closed	Canadian Cancer Trials Group	Canada

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Dexamethasone in the EU trials register (CTIS)

16 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Dexamethasone. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer 2024-518933-28-01 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Celcuity Inc	Finland, Bulgaria, Portugal + 11 more
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG-2 2026-525759-96-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 3	Authorised	Centre Hospitalier Universitaire De Toulouse	France
BASTION – Phase II Trial of BrECADD in HIV-Positive Patients with Advanced-Stage Classic Hodgkin Lymphoma 2025-521749-26-00 · Hemic and Lymphatic Diseases	Phase 2	Authorised	University Of Cologne	Germany
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5). 2025-524014-29-00 · Neoplasms	Phase 3	Authorised	AstraZeneca AB	Poland, Italy, Denmark + 4 more
Premedication with dexamethasone for preventing interstitial lung disease in patients with breast cancer treated with trastuzumab deruxtecan 2025-521798-15-00 · Neoplasms	Phase 3	Authorised	Istituto Di Ricerche Farmacologiche Mario Negri	Italy
An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates 2025-523222-40-00 · Pathological Conditions, Signs and Symptoms	Phase 2	Authorised	Medical University Of Vienna	Austria
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia 2025-522190-11-01 · Neoplasms	Phase 3	Authorised	Universitaetsklinikum Schleswig-Holstein AöR	Germany
ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial 2025-524976-40-00 · Respiratory Tract Diseases	Phase 3	Authorised	Centre Hospital Region Metz Thionville	France
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) 2025-522019-40-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Novartis Pharma AG	Italy, Spain, Germany + 4 more
Efficacy of intravenous dexamethasone in prolonging the duration of spinal anesthesia with chloroprocaine in knee arthroscopy. 2023-505247-39-00 · CTIS ↗ · Anesthesia and Analgesia	Phase 3	Authorised	Centre Medico Chirurgical Ambroise Pare Hartmann	France
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD) 2025-521090-14-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 2	Authorised	Assistance Publique Hopitaux De Paris	France
APICALE - Cervical facet injection of corticosteroids for the management of cervicobrachialgia : protocol for a randomized pilot study 2024-511790-30-00 · CTIS ↗ · Nervous System Diseases	Phase 3	Authorised	Assistance Publique Hopitaux De Paris	France
TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: a randomized trial » 2024-511807-41-01 · CTIS ↗ · Pathological Conditions, Signs and Symptoms	Phase 3	Authorised	Assistance Publique Hopitaux De Paris	France
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma 2024-519504-27-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Regeneron Pharmaceuticals Inc	Greece, Spain, Poland + 7 more
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020 2023-509392-17-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 3	Ongoing	Charite Universitaetsmedizin Berlin KöR	Netherlands, Czechia, Italy + 9 more
Erector Spinae Plane Block for acute low back pain: a prospective double-blind randomized multicenter study. ESP-BACK 2024-511595-32-00 · CTIS ↗ · Anesthesia and Analgesia	Phase 4	Authorised	Centre Hospitalier Universitaire De Montpellier	France

Dexamethasone across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

20 single-substance products containing Dexamethasone on the HPRA medicines list.

Dexafree 1mg/ml eye drops, solution in single dose containerLaboratoires Thea · PA1107/005/001 · Marketed
Dexamethasone 2mg TabletsAspen Pharma Trading Limited · PA1691/014/001 · Marketed
Dexamethasone Phosphate 4 mg/ml Solution for InjectionPfizer Healthcare Ireland Unlimited Company · PA0822/201/001 · Marketed
Dexamethasone Phosphate Krka 4 mg/ml solution for injection/infusionKRKA, d.d., Novo mesto · PA1347/091/001 · Marketed
Dexamethasone phosphate Noridem 4 mg/mL Solution for injectionNoridem Enterprises Limited · PA1122/020/001 · Marketed

All 20 Irish products →

Supply shortages

Dexamethasone Sodium Phosphate InjectionUS (FDA) · Current · updated 3 Nov 2026
Dexamethason 1,5 mg JenapharmGermany (BfArM) · Other reason · 1 Jun 2026 to 29 Jan 2027

EU shortages US shortages German shortages

Recent approvals

Ciprofloxacin And DexamethasoneFDA · 15 Oct 2026 · Generic (ANDA) · Alembic

EMA approvals tracker FDA approvals tracker

Conditions studied with Dexamethasone

322 conditions

Multiple Myeloma97Newly Diagnosed Multiple Myeloma10Acute Lymphoblastic Leukemia8Dexamethasone7Plasma Cell Myeloma6Relapsed/Refractory Multiple Myeloma6 Relapsed or Refractory Multiple Myeloma5Multiple Myeloma in Relapse5Myeloma5B Acute Lymphoblastic Leukemia5Refractory Multiple Myeloma4Childhood Leukemia, Acute Lymphoblastic4

All 322 conditions

Condition (as registered)	Trials
Multiple Myeloma	97
Newly Diagnosed Multiple Myeloma	10
Acute Lymphoblastic Leukemia	8
Dexamethasone	7
Plasma Cell Myeloma	6
Relapsed/Refractory Multiple Myeloma	6
Relapsed or Refractory Multiple Myeloma	5
Multiple Myeloma in Relapse	5
Myeloma	5
B Acute Lymphoblastic Leukemia	5
Refractory Multiple Myeloma	4
Childhood Leukemia, Acute Lymphoblastic	4
Hip Osteoarthritis	4
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent	3
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	3
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory	3
Acute Lymphoblastic Leukemia, in Relapse	3
Multiple Myeloma Refractory	3
Amyloidosis	3
Relapsed Refractory Multiple Myeloma (RRMM)	3
Myeloma Multiple	3
Multiple Myeloma (MM)	3
Pain, Postoperative	3
Breast Cancer	3
Postoperative Pain	3
B Lymphoblastic Lymphoma	3
Lymphoblastic Lymphoma, Childhood	2
Relapsed or Refractory Multiple Myeloma (RRMM)	2
Plasma Cell Myeloma Refractory	2
Relapsed Multiple Myeloma	2
Newly Diagnosed Multiple Myeloma (NDMM)	2
Lung Cancer	2
Surgery	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma	2
Dexamethasone Palmitate	2
Primary Immune Thrombocytopenia (ITP)	2
AL Amyloidosis	2
Acute Lymphoblastic Leukemia ALL	2
B Cell Acute Lymphoblastic Leukemia (B-ALL)	2
Postoperative Nausea and Vomiting	2
Nausea and Vomiting Caused by Chemotherapy	2
Immune Thrombocytopenia	2
Extramedullary Multiple Myeloma	2
Light Chain (AL) Amyloidosis	2
Mixed Phenotype Acute Leukemia	2
Acute Lymphoblastic Leukemia, Pediatric	2
Relapse Multiple Myeloma	2
Knee Arthroscopy	2
Recurrent B Acute Lymphoblastic Leukemia	2
Down Syndrome	2
Recurrent Lung Non-Small Cell Carcinoma	2
Dexmedetomidine	2
Prostatic Neoplasms, Castration-Resistant	1
Ovarian Cancer	1
Fallopian Tube Cancer	1
Primary Peritoneal Cancer	1
Prostate Cancer Metastatic	1
Metastatic Castration-resistant Prostate Cancer (mCRPC)	1
Prostatic Neoplasms	1
Relapsed Refractory Multiple Myeloma	1
Plasma Cell Myeloma Recurrent	1
Solid Tumor	1
Alzheimer's Disease	1
Dementia	1
Brain Diseases	1
Central Nervous System Diseases	1
Haematological Malignancy	1
Acute Myeloid Leukemia	1
Non Hodgkin Lymphoma	1
Relapsed and/or Refractory Multiple Myeloma (RRMM)	1
Non-Hodgkin Lymphoma	1
Advanced Solid Tumors	1
Malignant Neoplasm	1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	1
Non-small Cell Lung Cancer (NSCLC)	1
Hearing Loss	1
Prostate Cancer	1
Metastatic Castration Resistant Prostate Cancer	1
Metastatic Castration-sensitive Prostate Cancer	1
Kahler Disease	1
Myeloma, Plasma Cell	1
Lymphoma, Non-Hodgkin's	1
Esophageal Squamous Cell Carcinoma	1
Lung Neoplasm Malignant	1
Relapsed/Refractory Diffuse Large B-cell Lymphoma	1
Carcinoma, Non-Small-Cell Lung	1
Hodgkin Lymphoma, Adult	1
Pneumonia	1
Brain Metastases From Solid Tumors	1
Blood Pressure Management	1
Vitiligo	1
Child	1
Progressive Disease	1
Precursor B-Cell Lymphoblastic Leukemia	1
Colorectal Cancer Metastatic	1
Systemic AL Amyloidosis	1
T(11;14)	1
Sotoclax	1
Carfilzomib	1
AL Amyloidosis (AL)	1
t(11;14) Positive	1
Nausea With Vomiting Chemotherapy-Induced	1
Nasopharyngeal Carcinoma (NPC)	1
Relapsed/Refractory Large B-Cell Lymphoma	1
ETP-ALL	1
Amyloidosis; Systemic	1
Langerhans Cell Histiocytosis (LCH)	1
Non-squamous NSCLC	1
Acute Leukemia of Ambiguous Lineage	1
Adult T-cell Leukemia/Lymphoma	1
Nausea and Vomiting, Postoperative	1
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	1
T-lymphoblastic Lymphoma	1
Immune Thrombocytopenia (ITP)	1
Sudden Hearing Loss	1
Extracellular Vesicles	1
Acute Respiratory Distress Syndrome	1
Respiratory Distress Syndrome, Acute	1
Solid Tumor Cancer	1
Radiation-Induced Intestinal Injury	1
Hoarseness	1
Post Operative Complicaiton	1
Open Surgery	1
Hemophagocytic Syndrome	1
Pediatric Solid Tumor, Unspecified, Protocol Specific	1
Systemic Amyloidosis	1
Chemotherapy-induced Nausea and Vomiting	1
Thrombocytopenia	1
T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma	1
Nausea and Vomiting Caused by Trastuzumab Deruxtecan	1
Medulloblastoma	1
Inflammatory Bowel Disease (IBD)	1
CD - Crohn's Disease	1
UC - Ulcerative Colitis	1
Immune Thrombocytopenia With Positive ANA Antibodies	1
Acute Respiratory Distress Syndrome (ARDS)	1
Pancreatic Cancer	1
Epidural Block	1
Natural Killer/T-cell Lymphoma	1
Esophageal Stricture	1
Esophageal Neoplasms	1
CCND1 Translocation	1
Venetoclax	1
Paroxysmal Atrial Fibrillation	1
NKTCL	1
Selinexor	1
Rosai-Dorfman Disease	1
Primary Central Nervous System Lymphoma	1
Newly Diagnosed	1
High Risk	1
MRD	1
Primary Plasma Cell Leukemia	1
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)	1
Mature B-cell Non-Hodgkin Lymphoma	1
T Acute Lymphoblastic Leukemia	1
Heart Block Complete	1
Heart Block Second Degree	1
Severe Burns	1
Hospital Acquired Pneumonia	1
Intensive Care Pediatric	1
Acute Myeloid Leukemia (AML)	1
Cervicobrachial Neuralgia	1
Multiple Myeloma at First Relapse	1
Ocular Inflammation	1
Ocular Prostheses	1
B-cell Acute Lymphoblastic Leukemia	1
Pediatric Cancer	1
Multiple Myeloma, Newly Diagnosed	1
B-Cell Non-Hodgkin Lymphoma (B-NHL)	1
Smoldering Multiple Myeloma	1
Primary Immune Thrombocytopenia	1
Smouldering Myeloma	1
New Diagnosis Tumor	1
Deletion 17P Syndrome	1
Plasmablastic Lymphoma	1
Extramedullary Plasmacytoma	1
Radiation Necrosis	1
High Grade Glioma (III or IV)	1
Brain Metastasases	1
Radiation Toxicity	1
B-cell Non Hodgkin Lymphoma	1
Primary Aldosteronism	1
Intrahepatic Cholangiocarcinoma	1
Cancer	1
Postoperative Quality of Recovery	1
Health-Related Quality-of-Life	1
Quality of Life	1
Out-Of-Hospital Cardiac Arrest	1
Post-Cardiac Arrest Syndrome	1
Analgetic	1
Lung Cancer (NSCLC)	1
Video Assisted Thoracic Surgery (VATS)	1
Glucocorticoid	1
Informed Consent	1
Preference, Patient	1
Osteoarthritis, Hip	1
Adolescent Idiopathic Scoliosis (AIS)	1
Arthropathy of Hip	1
Hand Injuries and Disorders	1
Wrist Sprain	1
Ankle Disease	1
Foot Diseases	1
Knee Osteoarthritis	1
Hip Pain Chronic	1
Arthroplasty, Replacement, Shoulder	1
Glioblastoma	1
Steroids	1
Lymphoma, Follicular	1
Postoperative Recovery	1
PONV	1
Sudden Sensorineural Hearing Loss	1
Neuromuscular Block, Residual	1
Pain	1
Postoperative Nausea	1
Symptomatic Irreversible Pulpitis (SIP)	1
Dental Pain	1
Laparoscopic Appendectomy	1
Lymphoma	1
Germ Cell Cancer	1
Orbital Cellulitis	1
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA	1
Interstitial Lung Disease	1
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	1
AVB - Atrioventricular Block	1
Fetal AVB	1
Central Nervous System Leukemia	1
Post-Mastectomy Chronic Pain Syndrome	1
Lymphoblastic Leukemia	1
Acute Hypoxemic Respiratory Failure	1
Spinal Anesthesia	1
Prolonged Sensory Block	1
Prolonged Motor Block	1
Hodgkin Lymphoma	1
Back Pain Lower Back	1
Neck Pain	1
Radiculopathy Multiple Sites	1
Spinal Stenosis Cervicothoracic Region	1
Adult T Acute Lymphoblastic Leukemia	1
Ann Arbor Stage II Adult Lymphoblastic Lymphoma	1
Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	1
Ann Arbor Stage III Adult Lymphoblastic Lymphoma	1
Lymphoma, B-Cell	1
Acute Lymphoblastic Leukemia With Failed Remission	1
Dengue	1
Severe Dengue	1
Mosquito-Borne Diseases	1
Vector Borne Diseases	1
Postoperative Sleep Quality	1
Postoperative Behaviour	1
Postoperative Recovery in Children	1
Postoperative Nausea and Vomiting (PONV)	1
Acute Graft Versus Host Disease	1
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	1
RISS Stage I Plasma Cell Myeloma	1
RISS Stage II Plasma Cell Myeloma	1
Stage IV Lung Cancer AJCC v8	1
Advanced Lung Non-Small Cell Carcinoma	1
Stage III Lung Cancer AJCC v8	1
Stage IIIA Lung Cancer AJCC v8	1
DS Stage I Multiple Myeloma	1
DS Stage II Multiple Myeloma	1
DS Stage III Multiple Myeloma	1
Sacroiliac Joint Dysfunction	1
Sacro-Iliac Spondylosis	1
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive	1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	1
Hemophagocytic Lymphohistiocytoses	1
B-cell Lymphoma Recurrent	1
B-cell Lymphoma Refractory	1
CNS Metastases	1
Rebound Pain	1
Shoulder Injuries	1
Rotator Cuff Injuries	1
B Lymphoblastic Leukemia	1
Hematologic Malignancy	1
AML	1
ALL	1
BPDCN	1
Rheumatic Fever	1
Sydenham Chorea	1
Triple Negative Breast Cancer	1
Acute Lymphoblastic Lymphoma	1
ALL, Childhood	1
Lymphoblastic Leukemia, Acute, Childhood	1
Relapse	1
Waldenstrom Macroglobulinemia	1
Chronic Lymphocytic Leukaemia	1
Small Lymphocytic Lymphoma	1
Hematologic Malignancies	1
Multiple Myeloma, Refractory	1
Transplant Ineligible	1
Peripheral Neuropathy	1
Multiple Myeloma, Neoplasms	1
Sudden Sensorineural Hearing Loss (SSNHL)	1
Smoldering Plasma Cell Myeloma	1
Magnesium Sulphate	1
Adjuvant	1
Ultrasound	1
Muscle Weakness	1
Arthroplasty, Replacement, Hip	1
Impacted Mandibular Third Molar	1
Trismus	1
Facial Swelling	1
GIT Function	1
Cholecystectomy, Laparoscopic	1
İnguinal Hernia	1
Chronic Postoperative Pain	1
Quality of Recovery	1
Olanzapine	1
Carpal Tunnel	1
Ozone	1
Analgesia	1
Inflammatory Response	1
Postoperative Ileus	1
Postoperative Pain After Spinal Surgery	1
Sphenopalatine Ganglion Block	1
General Anesthesia	1
Quality of Surgical Field	1
Trans-Sphenoidal Endoscopic Hypophysectomy	1
Post Operative Pain	1
Brachial Plexus Blocks	1
Marginal Zone Lymphoma(MZL)	1

By country register

Register	Trials	Recruiting
Clinical trials in China	119	73
Clinical trials in France	85	42
Clinical trials in USA	84	40
Clinical trials in Spain	84	37
Clinical trials in Canada	76	35
Clinical trials in Australia	73	35
Clinical trials in Israel	72	35
Clinical trials in Germany	70	32
Clinical trials in Italy	68	31
Clinical trials in Poland	55	27
Clinical trials in Japan	55	25
Clinical trials in UK	52	29
Clinical trials in South Korea	52	28
Clinical trials in Netherlands	45	24
Clinical trials in Brazil	42	20
Clinical trials in Denmark	39	18
Clinical trials in Sweden	38	18
Clinical trials in Czechia	37	16
Clinical trials in Belgium	36	18
Clinical trials in Turkey	36	14
Clinical trials in Norway	34	19
Clinical trials in Mexico	30	12
Clinical trials in Taiwan	30	16
Clinical trials in Austria	27	14
Clinical trials in Egypt	21	15
Clinical trials in Switzerland	18	11
Clinical trials in Portugal	18	11
Clinical trials in Ireland	16	10
Clinical trials in Singapore	11	8
Clinical trials in India	10	5
EU register (CTIS)	16	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Dexamethasone trials

How many clinical trials are testing Dexamethasone?

341 current trials in our China, France, USA, Spain, Canada, Australia, Israel, Germany, Italy, Poland, Japan, UK, South Korea, Netherlands, Brazil, Denmark, Sweden, Czechia, Belgium, Turkey, Norway, Mexico, Taiwan, Austria, Egypt, Switzerland, Portugal, Ireland, Singapore and India registers name Dexamethasone (also registered as CI632D) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Dexamethasone trials recruiting patients?

Yes. 190 of the 341 trials are recruiting: 73 with sites in China, 42 with sites in France, 40 with sites in USA, 37 with sites in Spain, 35 with sites in Canada, 35 with sites in Australia, 35 with sites in Israel, 32 with sites in Germany, 31 with sites in Italy, 27 with sites in Poland, 25 with sites in Japan, 29 with sites in UK, 28 with sites in South Korea, 24 with sites in Netherlands, 20 with sites in Brazil, 18 with sites in Denmark, 18 with sites in Sweden, 16 with sites in Czechia, 18 with sites in Belgium, 14 with sites in Turkey, 19 with sites in Norway, 12 with sites in Mexico, 16 with sites in Taiwan, 14 with sites in Austria, 15 with sites in Egypt, 11 with sites in Switzerland, 11 with sites in Portugal, 10 with sites in Ireland, 8 with sites in Singapore and 5 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Dexamethasone clinical trials?

GlaxoSmithKline (14), Janssen Research & Development, LLC (13), Institute of Hematology & Blood Diseases Hospital, China (11) and Merck Sharp & Dohme LLC (10), among 171 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Dexamethasone clinical trials in Ireland?

Yes. 16 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Dexamethasone licensed in Ireland?

Yes. The HPRA medicines list includes 20 single-substance products containing Dexamethasone, for example Dexafree 1mg/ml eye drops, solution in single dose container (Laboratoires Thea). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Dexamethasone shortage?

The registers we track list 2 entries for Dexamethasone: US FDA: current; 1 German notice. Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dexamethasone works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dexamethasone works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dexamethasone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.